<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28915">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730299</url>
  </required_header>
  <id_info>
    <org_study_id>GC P#05.01.020</org_study_id>
    <nct_id>NCT02730299</nct_id>
  </id_info>
  <brief_title>Transplantation of Ex Vivo Expanded, UCB-derived, Stem &amp; Progenitor Cells vs. Unmanipulated UCB for HM Patients</brief_title>
  <official_title>A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gamida Cell ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gamida Cell ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, controlled, multicenter, international, Phase III, randomized
      study of transplantation of NiCord® versus transplantation of one or two unmanipulated,
      unrelated cord blood units in patients with acute lymphoblastic leukemia or acute myeloid
      leukemia, myelodysplastic syndrome or chronic myeloid leukemia, all with required disease
      features rendering them eligible for allogeneic transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Successful blood and marrow transplantation (BMT) requires the infusion of a sufficient
      number of hematopoietic stem/progenitor cells (HSPCs), capable of both homing to the bone
      marrow and regenerating a full array of hematopoietic cell lineages with early and late
      repopulating ability in a timely fashion.

      A major drawback of Umbilical Cord Blood (UCB) is the low stem cell dose available for
      transplantation, compared to mobilized peripheral blood (PB) or bone marrow. This low stem
      cell dose can compromise the chances of engraftment and contributes to delayed kinetics of
      neutrophil and platelet recovery, as well as other transplant outcomes.

      The aim of ex vivo expansion of cord blood is to provide a graft with sufficient numbers of
      cells that have rapid and robust in vivo neutrophil and platelet producing potential to
      enable successful transplantation.

      NiCord® is a stem/progenitor cell-based product composed of ex vivo expanded allogeneic
      cells from one entire unit of UCB. NiCord® utilizes the small molecule nicotinamide (NAM),
      as an epigenetic approach to inhibit differentiation and to increase the migration, bone
      marrow (BM) homing and engraftment efficiency of Hematopoietic Progenitor Cells (HPC)
      expanded in ex vivo cultures. The chief aim of the study is to compare the safety and
      efficacy of NiCord® single ex-vivo expanded cord blood unit transplantation to unmanipulated
      cord blood unit transplantation in patients with hematological malignancies following
      conditioning therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to neutrophil engraftment in participants following transplantation.</measure>
    <time_frame>must occur on or before 42 days post transplant</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hematological Malignancies</condition>
  <condition>Acute Lymphoblastic Leukemia (ALL)</condition>
  <condition>Acute Myelogenous Leukemia (AML)</condition>
  <condition>Chronic Myelogenous Leukemia (CML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>NiCord</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NiCord® is a cryopreserved stem/progenitor cell based product comprised of:
ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (NiCord® cultured fraction (CF))
the non-cultured cell fraction of the same Cord Blood Unit (CBU) (NiCord® Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.
Both fractions, i.e. NiCord® CF and NiCord® NF, will be kept frozen until they are thawed and infused on the day of transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unmanipulated CBU(s)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NiCord®</intervention_name>
    <arm_group_label>NiCord</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cord Blood Unit</intervention_name>
    <description>Cord blood unit</description>
    <arm_group_label>Unmanipulated CBU(s)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Applicable disease criteria

          -  Patients must have one or two partially HLA-matched CBUs

          -  Back-up stem cell source

          -  Adequate Karnofsky Performance score

          -  Sufficient physiological reserves

          -  Signed written informed consent

        Exclusion Criteria:

          -  HLA-matched donor able to donate

          -  Prior allogeneic HSCT

          -  Other active malignancy

          -  Active or uncontrolled infection

          -  Active/symptoms of central nervous system (CNS) disease

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Iddo Peleg, MSc. MBA</last_name>
    <phone>97226595630</phone>
    <email>iddo@gamida-cell.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph McGuirk, MD</last_name>
      <phone>913-945-6591</phone>
      <email>jmcguirk@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph McGuirk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Wagner, MD</last_name>
      <phone>612-626-2961</phone>
      <email>wagne002@umn.edu</email>
    </contact>
    <investigator>
      <last_name>John Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Horwitz, MD</last_name>
      <phone>919-668-1045</phone>
      <email>mitchell.horwitz@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Mitchell Horwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Children's</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rabi Hanna, MD</last_name>
      <phone>216-444-0663</phone>
      <email>Hannar2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Rabi Hanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Maziarz, MD</last_name>
      <phone>503-494-4606</phone>
      <email>maziarzr@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Maziarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Madan Jagasia, MD</last_name>
      <phone>615-936-8422</phone>
      <email>madan.jagasia@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>Madan Jagasia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3503 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaap Jan Boelens, MD</last_name>
      <phone>+31-88-7554003</phone>
      <email>J.J.Boelens@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Jaap Jan Boelens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Valcárcel, MD, PhD</last_name>
      <phone>+34-934 893 000</phone>
      <phone_ext>6417</phone_ext>
      <email>dvalcarcel.vhebron@me.com</email>
    </contact>
    <investigator>
      <last_name>David Valcárcel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Sanz, MD</last_name>
      <phone>+34 (96) 386-2709</phone>
      <email>sanz_gui@gva.es</email>
    </contact>
    <investigator>
      <last_name>Guillermo Sanz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 12, 2016</lastchanged_date>
  <firstreceived_date>March 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
